Active technical traders often steer clear of pharmaceutical stocks due to their volatile and unpredictable nature. The risk is often too great, as you can see a stock’s price skyrocket or plummet based on a key FDA decision regarding a drug. Take for example, Anthera Pharmaceuticals (ANTH). Anthera actively and brazenly pushed its acute coronary syndrome therapy, Varespladib, though trials in…
View the full post at http://blog.t3live.com
